An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial
about
Antiplatelet agents for chronic kidney diseaseAntiplatelet agents for chronic kidney diseaseAdenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitusTicagrelor: molecular discovery to clinical evidence: ticagrelor: a novel antiplatelet agentEffect of addition of clopidogrel to aspirin on mortality: systematic review of randomized trialsIntracranial plaque enhancement in patients with cerebrovascular events on high-spatial-resolution MR images.Is the Combination of Aspirin and Clopidogrel always Better than Aspirin Alone? Or will it be too much of a good thing?Predictors of mortality in patients with lacunar stroke in the secondary prevention of small subcortical strokes trial.Differential effect of low-dose aspirin for primary prevention of atherosclerotic events in diabetes management: a subanalysis of the JPAD trialCurrent antiplatelet treatment strategy in patients with diabetes mellitus.Contemporary use of dual antiplatelet therapy for preventing cardiovascular eventsCombination aspirin and clopidogrel for secondary prevention of ischemic stroke.Resistance to aspirin and clopidogrel therapy.The evolution of antiplatelet therapy in cardiovascular disease.Clinical implications of platelet-vessel interaction.Aspirin resistance.The association between TNF-α and erectile dysfunction complaints.Synthesis and in Vitro and in Vivo Anticoagulant and Antiplatelet Activities of Amidino- and Non-Amidinobenzamides.
P2860
Q24197614-401CCAD7-AA03-44E3-9F0E-925D92C31058Q24200752-CD1EB167-78B3-4BB9-B491-FF5CA69990D8Q24203035-C5785A94-78D0-4632-8DEA-91912816301EQ26829967-03B1E592-C7B0-42D9-AA4B-DADBCEAA4B4DQ26999848-9A942AB0-103E-4C92-8982-005FB626681DQ30744971-559A3493-27C0-4A0D-97AC-68413BF8EC07Q34220492-A7BDB666-44C4-48CA-8535-61BA39CBA39CQ34244196-FF049240-A701-4566-9426-8390CED4A3C0Q35043219-ACED8531-A43A-4DB2-811B-EEE8EB3C15B7Q35544048-9331C4F9-59AC-4110-96B7-C3DE4AB77CC1Q35963386-D6BD43BA-E47E-4197-9807-C1E162E1E048Q37691449-C6CA3971-029D-456F-BBF8-593AE180C3F5Q37807524-07F72295-A239-47A2-9E0B-8C08532D1352Q37900470-7D72AC78-456A-4C3F-8707-3001ABFEFDBCQ38070127-A362D3A7-B5EB-486B-AC77-55BA1BDCF503Q42641720-0F0862CD-7E2C-4AC8-8A63-EBA3B1D25BD5Q44595883-1E4D1D8D-8B96-4486-8924-8811AFE5E761Q53094376-61270624-FFAC-4611-ABD3-43CF3331305B
P2860
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
An analysis of mortality rates ...... pulation of the CHARISMA trial
@ast
An analysis of mortality rates ...... pulation of the CHARISMA trial
@en
An analysis of mortality rates ...... pulation of the CHARISMA trial
@nl
type
label
An analysis of mortality rates ...... pulation of the CHARISMA trial
@ast
An analysis of mortality rates ...... pulation of the CHARISMA trial
@en
An analysis of mortality rates ...... pulation of the CHARISMA trial
@nl
prefLabel
An analysis of mortality rates ...... pulation of the CHARISMA trial
@ast
An analysis of mortality rates ...... pulation of the CHARISMA trial
@en
An analysis of mortality rates ...... pulation of the CHARISMA trial
@nl
P2093
P50
P356
P1476
An analysis of mortality rates ...... pulation of the CHARISMA trial
@en
P2093
Keith A A Fox
Koon-Hou Mak
Marcus D Flather
P Gabriel Steg
Thomas A Pearson
Thomas H Wang
Werner Hacke
William E Boden
P304
P356
10.1093/EURHEARTJ/EHM274
P407
P577
2007-09-01T00:00:00Z